Login or sign up
For business

Calypso Biotech

4.4· 9 reviews
Average ratingGreat
4.4/ 5

Based on 9 reviews

556%
433%
311%
20%
10%
Ask AI

What reviewers say about Calypso Biotech

Based on 9 reviews on Trustburn · updated 59 days ago

Customers generally praise Calypso Biotech for its user-friendly website, high-quality products, and friendly, responsive customer service, with most reviews being positive. A small number of reviewers felt that the support team could be more helpful or knowledgeable, and one described the overall experience as merely average.
What does Calypso Biotech do?

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland, founded in 2013 as a spin-off from Merck Serono. It develops proprietary antibody candidates and operates as a nimble, semi-virtual organization focused on auto-immune diseases and biologics.

What are the most common complaints about Calypso Biotech?

The most common complaint, based on the reviews on file, relates to customer service, particularly slow response times and insufficient support or product knowledge from the support team. A few reviewers also noted that the website's product information could be more helpful.

AI-generated from reviews on this page. Verify anything important with the company directly.

Denise Scoltock
Reviews 1

This company is doing an average job. Their website is informative and user-friendly. However, there is room for improvement in terms of customer service. The response time could be faster, and their support team needs to be more knowledgeable about their products.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Calypso Biotech

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.